Mitotane
Brand names: Lysodren · Active ingredient: Mitotane
In short: LYSODREN is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenocortical carcinoma (ACC).
What is Mitotane used for?
LYSODREN is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenocortical carcinoma (ACC).
âš Boxed warning (FDA's strongest warning)
Patients treated with LYSODREN are at increased risk for developing adrenal crisis in the setting of shock, severe trauma or infection that may lead to death.
If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. Monitor patients closely for infections and instruct patients to contact their physician immediately if injury, infection, or any other concomitant illness occurs .
Mitotane dosage
Before initiating LYSODREN, evaluate pelvic ultrasound in premenopausal women, liver functions tests and complete blood count
.
LYSODREN is a hazardous drug. Advise caregivers to wear disposable gloves when handling LYSODREN tablets
.
Recommended Dosage
The recommended initial dose of LYSODREN is 2000 mg to 6000 mg orally, in three or four divided doses per day.
Monitor mitotane plasma levels and increase the dose based on patient tolerance and clinical response incrementally to achieve a mitotane plasma level of 14 to 20 mg/L, or as tolerated. Consider monitoring mitotane plasma levels every 2 weeks after starting treatment and after each dose adjustment.
The target plasma level is usually reached within a period of 3 to 5 months.
Monitor mitotane plasma levels periodically (e.g., monthly). Severe neurotoxicity may occur with levels > 20 mg/L.
Dose Adjustments, Monitoring and Discontinuation
In case of mitotane plasma levels above 20 mg/L without toxicities, consider reducing the dose by 50 to 75%.
Monitor mitotane plasma levels regularly (e.g., every two months) after discontinuation of treatment. Due to the prolonged half-life, significant levels may persist for weeks after cessation of therapy.
LYSODREN is lipophilic and accumulates in adipose tissue. Despite maintaining a constant dose, mitotane levels may suddenly increase. Monitor mitotane plasma levels even when LYSODREN has been withheld as adipose tissue may continue to release mitotane
. Due to adipose tissue accumulation of mitotane, close monitoring of mitotane plasma levels is recommended in overweight patients and patients with recent weight loss.
Administration
Swallow LYSODREN tablets whole; do not crush, chew or split.
Take LYSODREN with food. Timing of the dose relative to meals must be consistent. Administration with high fat food enhances absorption
.
Do not take tablets showing signs of deterioration.
Caregivers should wear disposable gloves when handling the tablets. Avoid exposure to crushed and/or broken tablets. If contact with crushed/broken tablets occurs, wash the contaminated skin immediately and thoroughly.
If a patient misses a dose, instruct the patient to take the next dose as scheduled.
If a patient vomits after taking a dose, instruct the patient to take the next dose as scheduled.
The recommended dosage reduction for adverse reactions is to decrease the usual daily dose by 500 – 1000 mg.
Table 1 describes the dosage modifications for specific adverse reactions.
Adverse Reaction | Severity
Severity defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. …
How to take Mitotane — instructions & advice from the label
17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Adrenal Insufficiency and Adrenal Crisis
• Advise patients of the risk of adrenal suppression that may require steroid treatment and interruption or discontinuation of LYSODREN .
• Advise patients to discontinue LYSODREN in the case of shock, severe trauma or infection and contact their healthcare provider immediately .
• Advise patients to inform their healthcare provider of any planned surgeries .
Central Nervous System Toxicity
• Advise patients to contact their healthcare provider if they experience new or worsening symptoms of central nervous system (CNS) toxicity including sedation, lethargy and vertigo .
• Instruct patients not to drive or operate hazardous machinery if they are experiencing CNS adverse reactions .
Ovarian Macrocysts in Premenopausal Women
• Advise premenopausal women that their healthcare provider will monitor them with routine imaging and to contact their healthcare provider if they experience gynecological symptoms such as vaginal bleeding and/or pelvic pain . …
Warnings & precautions
Do not take this medicine if: None.
Adrenal Insufficiency
LYSODREN can cause adrenal insufficiency or worsen existing adrenal insufficiency in patients with adrenocortical carcinoma.
Monitor for both glucocorticoid and mineralocorticoid insufficiency and replace systemic corticosteroids accordingly. Due to increased steroid clearance and increase of steroid-binding protein, high-dose replacement therapy may be required and free cortisol and corticotropin (ACTH) should be monitored to adapt the systemic corticosteroids.
Withhold, reduce the dose, or permanently discontinue LYSODREN based on severity
.
Adrenal Crisis in the Setting of Shock, Severe Trauma or Infection
LYSODREN can cause adrenal suppression and adrenal crisis in the setting of shock, severe trauma or infection.
Advise patients of the signs and symptoms of adrenal suppression and to contact their healthcare provider immediately if shock, trauma, infection, or adrenal suppression occurs. Withhold LYSODREN before planned surgeries.
Temporarily withhold LYSODREN during shock, trauma, infection or adrenal suppression
.
Provide supportive care and administer systemic corticosteroids until recovery.
LYSODREN can cause central nervous system toxicity, including sedation, lethargy, and vertigo
.
Monitor behavioral and neurologic assessments and mitotane plasma levels at regular intervals. Mitotane plasma levels exceeding 20 mg/L are associated with a greater incidence of toxicity.
In cases of cognitive dysfunction, thyroid function should be evaluated as mitotane may induce hypothyroidism.
LYSODREN can impair the ability to drive and operate machinery. Advise patients not to drive or operate hazardous machinery if they are experiencing CNS adverse reactions. Withhold, reduce the dose, or permanently discontinue LYSODREN based on severity
. …
Mitotane side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
• Adrenal Insufficiency and Adrenal Crisis
• Central Nervous System Toxicity
• Ovarian Macrocysts in Premenopausal Women
• Hepatotoxicity
• Hematologic Toxicity
• Prolonged Bleeding Time
• Hormone Binding Protein
• Embryo-Fetal Toxicity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Reported adverse reactions include:
Metabolism and nutrition disorders: Anorexia
Gastrointestinal disorders: Epigastric discomfort, nausea, vomiting, diarrhea, mucosal inflammation, dyspepsia
Nervous system disorders: Dizziness, vertigo, confusion, headache, ataxia, mental impairment, weakness, dysarthria, paresthesia, polyneuropathy, movement disorder, balance disorder, dysgeusia
Skin and subcutaneous tissue disorders: Rash, pruritus, hypersensitivity reactions
Blood and lymphatic system disorders: Leukopenia, anemia, thrombocytopenia, prolonged bleeding time, hematuria, hemorrhagic cystitis
Endocrine: Growth retardation, hypothyroidism
Eye disorders: Maculopathy, visual blurring, diplopia, lens opacity, retinopathy
Hepatobiliary disorders: Hepatitis, elevation of liver enzymes, liver injury (hepatocellular/cholestatic/mixed)
Reproductive system and breast disorders: Gynecomastia, …
Drug interactions
Spironolactone
Spironolactone may block the action of mitotane. Avoid concomitant use of mitotane with spironolactone
.
Certain CYP3A substrates
Mitotane is a strong CYP3A inducer. Concomitant use of LYSODREN may decrease the levels of CYP3A substrates, which may reduce the activity of these substrates
.
Avoid concomitant use of LYSODREN with other CYP3A substrates, where minimal level changes may lead to serious therapeutic failures. If concomitant use cannot be avoided, modify the dosage of the CYP3A substrate in accordance with the approved product labeling.
Hormonal Contraceptives
Avoid concomitant use of LYSODREN with hormonal contraceptives
.
Warfarin
Mitotane may induce the metabolism of warfarin, which may reduce its level and its efficacy
.
Avoid concomitant use of LYSODREN with warfarin. If concomitant use cannot be avoided, monitor INR more frequently and adjust warfarin dose as recommended in accordance with the recommendations in the warfarin Prescribing Information.
About this medicine
LYSODREN (mitotane) is an oral adrenal cytotoxic agent. The chemical name is (±)-1,1-dichloro-2-(
o-chlorophenyl)-2-(
p-chlorophenyl) ethane (also known as o,p'-DDD). The chemical structure is:
Mitotane is a white granular solid composed of clear colorless crystals. It is tasteless and has a slight pleasant aromatic odor. It is soluble in ethanol and has a molecular weight of 320.05.
Inactive ingredients in LYSODREN are: microcrystalline cellulose, polyethylene glycol 3350, silicon dioxide, and starch.
How it works: Mitotane is an adrenal cytotoxic agent with an unknown mechanism of action. Mitotane modifies the peripheral metabolism of steroids and directly suppresses the adrenal cortex. A reduction in 17-hydroxycorticosteroids in the absence of decreased corticosteroid levels and increased formation of 6-β-hydroxycortisol have been reported.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 4046a224-8832-daa2-e063-6294a90a11d7. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate